Biotech Stock News (CLVS)(SNTA)
Clovis Oncology (NASDAQ:CLVS) On Tuesday April 13, 2016 Clovis Oncology announced that the FDA advisory panel concluded that the company’s drug, Rociletinib, had insufficient data to warrant approval. Not only did the FDA panel advise against approval, it shot down the drug with a vote of 12 “against and 1 “for” approval. This was the … Read more